Scott Owen

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 347 citations · Full text

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 91 citations · Full text

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution

M. Azoulay, Fabiano Santos, George Shenouda et al. · Journal of Neuro-Oncology · 2017 · 82 citations

Neuro-oncology, Surgical Oncology, Medicine +11

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 78 citations · Full text

Nivolumab Versus Docetaxel, Medicine, Pharmacology +7

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 76 citations

Real-world Multicentre Study, Medicine, Historical Cohort +9